Zhanna OLIYNYK, Anastasiia MARYNCHENKO, Mariya RUDYK, Taisa DOVBYNCHUK, Natalie DZUBENKO, Ganna TOLSTANOVA

FUNCTIONAL CHANGES IN PERIPHERAL PHAGOCYTES IN RATS WITH LPS-INDUCED PARKINSON'S DISEASE

Sustained neuroinflammation is considered to be a leading contributor to progressive neuron damage of the substantia nigra, leading to the development of Parkinson’s disease (PD). Systemic inflammation (SI) correlates with neuroinflammation as PD progresses, and exacerbates neurodegeneration. Phagocytes are key players in both neuroinflammation and SI. SI manifestation in commonly used animal models of PD is an unexplored question.LPS-induced PD is usually used for the study of the inflammation in the PD pathophysiology. The aim of this study was to examine metabolic profile of peripheral phagocytes in rats with LPS-induced PD. LPS-induced PD was accompanied by the neutrophilia, the decrease of circulating lymphocyte proportion, and as a result - by doubling the neutrophil-to-lymphocytes ratio. Reactive oxygen species generation was higher in circulating phagocytes from rats with PD (by 1.3 times in neutrophils and by more than 5 times- in monocytes) as compared to control animals. Wherein, phagocytic activity was lower in neutrophils by 1.2 times and in monocytes - by 2.6 times as compared to the control. These data indicate systemic inflammatory process in LPS lesioned rats.Thus, LPS-induced PD reproduces systemic inflammation spread, which is inherent for progressive PD.

PDF

___

[1] Ferrari, C.C. and Tarelli, R., “Parkinson'sdisease and systemic inflammation”, Parkinsons Dis. 22, 436-813, 2011.
[2] Gundersen, V., “Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?”, Frontiers in neuroscience, 14, 580311, 2021.
[3] Côté, M., Poirier, A., Aubé, B., Jobin, C., Lacroix, S., &Soulet, D., “Partial depletion of the proinflammatory monocyte population is neuroprotective in the myenteric plexus but not in the basal ganglia in a MPTP mouse model of Parkinson's disease”, Brain, behavior, and immunity, 46, 154–167, 2015.
[4] Hasegawa, Y., Inagaki, T., Sawada, M., & Suzumura, A., “Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease”, Acta neurologica Scandinavica, 101(3), 159–164, 2000.
[5] Ivan, D. C., Walthert, S., Berve, K., Steudler, J., & Locatelli, G., “Dwellers and Trespassers: Mononuclear Phagocytes at the Borders of the Central Nervous System”, Frontiers in immunology, 11, 609921, 2021.
[6] Ortiz, G. G., González-Usigli, H., Pacheco-Moisés, F. P., Mireles-Ramírez, M. A., Sánchez-López, A. L., Torres- Sánchez, E. D., ... González, V. S., “Physiology and pathology of neuroimmunology: Role of inflammation in parkinson’s disease”, Physiology and Pathology of Immunology. IntechOpen, 2017.
[7] Gasparotto, J., Ribeiro, C. T., Bortolin, R. C., Somensi, N., Rabelo, T. K., Kunzler, A., Souza, N. C., Pasquali, M., Moreira, J., &Gelain, D. P., “Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA- induced dopaminergic denervation”, Scientific reports, 7(1), 8795, 2017.
[8] Liu, M., & Bing, G., “Lipopolysaccharide animal models for Parkinson's disease”, Parkinson's disease, 327089, 2011.
[9] Yıldızhan, K., Nazıroğlu, M. “Glutathione Depletion and Parkinsonian Neurotoxin MPP+-Induced TRPM2 Channel Activation Play Central Roles in Oxidative Cytotoxicity and Inflammation in Microglia”, Molecular neurobiology, 57(8), 3508-3525, 2020.
[10] Fricke, I.B., Viel, T., Worlitzer, M.M., Collmann, F.M., Vrachimis, A., Faust, A., Wachsmuth, L., Fabe, C., Dollé, F., Kuhlmann, M.T., Schäfers, K., Hermann, S., Schwamborn, J.C., Jacobs, A.H. “6-hydroxydopamine- induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis”, The European journal of neuroscience, 43(10),1352-1365, 2016.
[11] Hoban, D. B., Connaughton, E., Connaughton, C., Hogan, G., Thornton, C., Mulcahy, P., Moloney, T. C., & Dowd, E., “Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat”, Brain, behavior, and immunity, 27(1), 91–100, 2013.
[12] Rudyk, M., Hurmach, I., Svyatetska, V., Prysyazhnyuk, O., Dovbynchuk, T., Skachkova, O., TolstanovaG., Skivka, L., “Peripheral phagocyte characteristics as markers of systemic inflammation in rats with different stages of Parkinson's disease”, EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (Vol. 48, pp. 73-73). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY 89, 2018.
[13] Rudyk, M. P., Opeida, I. V., Svyatetska, V. M., Prysiazhniuk, A. I., Dovbynchuk, T. V., Khranovska, N. M., Tolstanova G.M., Skivka, L. M., “Microglia and circulating phagocyte metabolic profile in rats with MPTP-induced Parkinson's disease and concomitant ulcerative colitis”, EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (Vol. 47, pp. 151-152). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2017.
[14] Oliynyk, Z., Senchylo, N., Dovbynchuk, T., Stepanenko, S., & Guzik, M., “Reactive astrogliosis in rats with LPS-induced Parkinson's disease”, Bulletin of Taras Shevchenko National University of Kyiv- Biology, 80(1), 19-25, 2020.
[15] Talanov, S.A., Oleshko, N.N., Tkachenko, M.N., Sagach, V.F., “Pharmacoprotective influences on different links of the mechanism underlying 6- hydroxydopamine-induced degeneration of nigro- striatal dopaminergic neurons”, Neurophysiology 38 (2), 128-133, 2006.
[16] Walsh, S., Finn, D. P., & Dowd, E., “Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine- induced axonal and terminal lesion models of Parkinson's disease in the rat”, Neuroscience, 175, 251–261, 2011.
[17] Rudyk, M., Pozur, V.V., Voieikova, D., Hurmach, Y., Khranovska, N., Skachkova, O., Svyatetska, V., Fedorchuk, O.G., Skivka, L., Berehova, T.V., &Ostapchenko, L., “Sex-based differences in phagocyte metabolic profile in rats with monosodium glutamate-induced obesity”, Scientific Reports, 8, 2018.
[18] Deng, I., Corrigan, F., Zhai, G., Zhou, X., &Bobrovskaya, L., “Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease”, Brain, Behavior, & Immunity - Health, Volume 4, 2020.
[19] Björklund, A., & Dunnett, S. B, “The Amphetamine Induced Rotation Test: A Re-Assessment of Its Use as a Tool to Monitor Motor Impairment and Functional Recovery in Rodent Models of Parkinson's Disease”, Journal of Parkinson's disease, 9(1), 17–29, 2019.
[20] Iancu, R., Mohapel, P., Brundin, P., Paul, G. “Behavioral characterization of a unilateral 6-OHDA- lesion model of Parkinson's disease in mice”, Behavioural brain research, 162(1), 1-10, 2005.
[21] Miyanishi, K., Choudhury, M. E., Watanabe, M., Kubo, M., Nomoto, M., Yano, H., & Tanaka, J., “Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model.”, Neurochemistry international, 122, 38–46, 2019.
[22] Eidson, L. N., Kannarkat, G. T., Barnum, C. J., Chang, J., Chung, J., Caspell-Garcia, C., Taylor, P., Mollenhauer, B., Schlossmacher, M. G., Ereshefsky, L., Yen, M., Kopil, C., Frasier, M., Marek, K., Hertzberg, V. S., & Tansey, M. G., “Candidate inflammatory biomarkers display unique relationships with alpha- synuclein and correlate with measures of disease severity in subjects with Parkinson's disease”, Journal of neuroinflammation, 14(1), 164, 2017.
[23] Choi, S. J., Hong, Y. H., Kim, S. M., Shin, J. Y., Suh, Y. J., & Sung, J. J., “High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis”, Scientific reports, 10(1), 428, 2020.
[24] Umehara, T., Oka, H., Nakahara, A., Matsuno, H., & Murakami, H., “Differential leukocyte count is associated with clinical phenotype in Parkinson's disease”, Journal of the neurological sciences, 409, 116638, 2020.
[25] Schulz, D., Severin, Y., Zanotelli, V., & Bodenmiller, B., “In-Depth Characterization of Monocyte-Derived Macrophages using a Mass Cytometry-Based Phagocytosis Assay”, Scientific reports, 9(1), 1925, 2019.
[26] Veglia, F., Perego, M., & Gabrilovich, D., “Myeloid- derived suppressor cells coming of age”, Nature immunology, 19(2), 108–119, 2018.